DMT310-009 Topical in the Treatment of Acne Vulgaris
← catalyst calendarSponsored by Dermata Therapeutics (industry) · DRMA — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
520actual
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-12-08 | actual | When the study began enrolling |
| Primary completion | 2025-03-31 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-04-30 | actual | The whole study's end, after follow-up |
| First posted | 2023-10-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Acne Vulgaris
Interventions
- Drug: DMT310
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFEfficacy as measured by lesion counts
measured 12 weeks
Efficacy as measured by Investigator Global Assessment (IGA)
measured 12 weeks
Permalink · DRMA's whole pipeline · Catalyst calendar · Every registered study · What changed